Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R
1
is a polar group. In some embodiments, R
1
is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof. R
2
and R
3
are independently selected from the group consisting of hydrogen and substituted or unsubstituted hydrocarbyl; each R
4
is independently selected from the group consisting of halogen and substituted or unsubstituted hydrocarbyl and n is an integer from 0 to 4; each R
5
is independently selected from the group consisting of halo and substituted or unsubstituted hydrocarbyl and m is an integer from 0 to 3; and R
6
is substituted or unsubstituted cyclohexyl; and the pharmaceutically acceptable salts thereof.
本发明提供了周围限制的
脂肪酸酰胺酶(FAAH)
抑制剂。这些化合物可以抑制FAAH活性并增加中枢神经系统(CNS)外的阿那and胺
水平。尽管它们相对无法进入大脑和脊髓,但这些化合物可以减弱炎症和周围神经损伤啮齿动物模型中表现持续性疼痛的行为反应,并抑制与伤害处理有关的脊髓区域的神经元激活。CB1受体阻断可以防止这些效应。因此,本发明还提供了治疗抑制周围FAAH会有益的疾病的方法和制药组合物。本发明的化合物符合以下公式(I):其中R1是极性基团。在某些实施例中,R1选择自羟基和其生理上可
水解的酯。R2和R3分别选择自氢和取代或未取代的烃基;每个R4独立选择自卤素和取代或未取代的烃基,n为0到4的整数;每个R5独立选择自卤素和取代或未取代的烃基,m为0到3的整数;R6是取代或未取代的环己基;以及其药物可接受的盐。